The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin

J Neurochem. 2004 Nov;91(4):900-10. doi: 10.1111/j.1471-4159.2004.02769.x.

Abstract

Recently, erythropoietin (EPO) and the nonerythropoietic derivative asialoEPO have been linked to tissue protection in the nervous system. In this study, we tested their effects in a model of neonatal hypoxia-ischemia (HI) in 7-day-old rats (unilateral carotid ligation and exposure to 7.7% O(2) for 50 min). EPO (10 U/g body weight = 80 ng/g; n = 24), asialoEPO (80 ng/g; n = 23) or vehicle (phosphate-buffered saline with 0.1% human serum albumin; n = 24) was injected intraperitoneally 4 h before HI. Both drugs were protective, as judged by measuring the infarct volumes, neuropathological score and gross morphological score. The infarct volumes were significantly reduced by both EPO (52%) and asialoEPO (55%) treatment, even though the plasma levels of asialoEPO had dropped below the detection limit (1 pm) at the onset of HI, while those of EPO were in the nanomolar range. Thus, a brief trigger by asialoEPO before the insult appears to be sufficient for protection. Proteomics analysis after asialoEPO treatment alone (no HI) revealed at least one differentially up-regulated protein, synaptosome-associated protein of 25 kDa (SNAP-25). Activation (phosphorylation) of ERK was significantly reduced in asialoEPO-treated animals after HI. EPO and the nonerythropoietic asialoEPO both provided significant and equal neuroprotection when administered 4 h prior to HI in 7-day-old rats. The protection might be related to reduced ERK activation and up-regulation of SNAP-25.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Animals, Newborn
  • Asialoglycoproteins / biosynthesis
  • Asialoglycoproteins / blood
  • Asialoglycoproteins / pharmacokinetics
  • Asialoglycoproteins / therapeutic use*
  • Brain Infarction / pathology
  • Brain Infarction / prevention & control
  • Disease Models, Animal
  • Erythropoietin / analogs & derivatives*
  • Erythropoietin / biosynthesis
  • Erythropoietin / blood
  • Erythropoietin / pharmacokinetics
  • Erythropoietin / therapeutic use*
  • Female
  • Hypoxia-Ischemia, Brain / drug therapy*
  • Hypoxia-Ischemia, Brain / pathology
  • Male
  • Membrane Proteins / metabolism
  • Nerve Tissue Proteins / metabolism
  • Proteomics / methods
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Synaptosomal-Associated Protein 25
  • Treatment Outcome

Substances

  • Asialoglycoproteins
  • Membrane Proteins
  • Nerve Tissue Proteins
  • Snap25 protein, rat
  • Synaptosomal-Associated Protein 25
  • asialoerythropoietin
  • Erythropoietin